The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II Study of Docetaxel (D) and Cisplatin (CDDP) in Advanced Urothelial Cancer: Preliminary Results.
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Otsuka (Inst); Takeda (Inst)
 
Daisuke Sakai
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hisato Kawakami
No Relationships to Disclose
 
Naotoshi Sugimoto
Research Funding - Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly Japan; Merck Sharp & Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Taito Esaki
Honoraria - Chugai Pharma; Eisai; Lilly Japan; Merck Serono; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; DS Pharma Biomedical; Lilly Japan; Merck Serono; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Tadamichi Denda
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Sanofi (Inst)
 
Akitaka Makiyama
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Naoki Izawa
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Chugai Pharma; Eisai; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)
 
Shinya Tokunaga
No Relationships to Disclose
 
Toshikazu Moriwaki
Speakers' Bureau - Chugai Pharma; Merck Serono; Novelpharm; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Akihito Tsuji
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Yasuhiro Koh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Illumina; Kyowa Hakko Kirin; Raindance Technologies
Consulting or Advisory Role - Tosoh Corporation
Research Funding - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Hitachi Chemical; Sumitomo electric Ind.
 
Junji Kishimoto
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha